Listar PSB_Articles por autoría "8af45e0f-fdd8-40b2-9302-4b4d0b519a51"
Mostrando ítems 1-1 de 1
-
Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost–utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)
Colomer-Carbonell, Ariadna; Sanabria-Mazo, Juan P.; Hernández-Negrín, Halbert; Borràs, Xavier; Suso-Ribera, Carlos; García-Palacios, Azucena; Muchart, Jordi; Munuera, Josep; D’Amico, Francesco; Maes, Michael; Younger, Jarred W.; Feliu-Soler, Albert; Rozadilla-Sacanell, Antoni; Luciano, Juan Vicente BMJ Publishing Group (2022-01)Introduction: There is evidence that low-dose naltrexone (LDN; <5.0 mg/day) reduces pain and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no randomised controlled trials with long-term ...